What Peptides Can You Take With Tirzepatide? Common Pairings and What Not to Combine

Tirzepatide is a single peptide that activates two incretin receptors, GIP and GLP-1. It acts on appetite centres in the brain, slows gastric emptying and changes insulin and glucagon signalling, and the weight change reported in its trials follows from people eating less over a long period. It is not a stimulant or a thermogenic, and it does not force the body to burn anything. The full reference is at what is tirzepatide.

In the STEP 1 body-composition substudy of semaglutide, both fat mass and lean mass fell, though fat fell by more and the proportion of lean mass rose. Losing muscle alongside fat leaves you lighter, weaker and with a lower resting metabolic rate, which is the mechanism behind regain. Appetite suppression this strong also makes under-eating protein the default. That is the honest rationale for most of the pairings below: a second agent aimed at lean tissue, visceral fat or how muscle uses fuel, used with training and protein rather than instead of them.

No trial shows that any adjunct adds weight loss on top of a GLP-1 medication, and no trial shows that a growth hormone secretagogue preserves lean mass during GLP-1 treatment. The pairings are grounded in mechanism and prescriber experience. That is a reasonable basis for prescribing; it is not evidence that a combination works better than tirzepatide alone. More on weight-management options is in best peptides for weight loss.

Tesamorelin is a growth-hormone-releasing hormone analogue that prompts your pituitary to release your own growth hormone. It has randomised placebo-controlled trials, in people with HIV and abdominal fat accumulation and in one trial of abdominally obese adults without HIV, measuring visceral fat on CT. Its approved label calls the drug weight-neutral: the trials measured visceral fat, not kilograms.

That is exactly why it is paired. The tesamorelin reference describes it as sometimes prescribed together with a GLP-1, with the GLP-1 addressing total weight and tesamorelin addressing visceral fat. Growth hormone reduces insulin sensitivity while GLP-1 medications act in the other direction, so your physician watches glucose across both. It is dosed at 0.25 mL (25 units) Monday through Friday nights at bedtime. See what is tesamorelin and how to get tesamorelin prescribed.

These are the other growth-hormone-axis options. CJC-1295 and sermorelin act at the GHRH receptor; ipamorelin acts at the ghrelin receptor. Some prescribers add a growth-hormone-axis peptide such as CJC-1295 / Ipamorelin alongside a GLP-1 with lean tissue in mind, as an adjunct to training and protein rather than a replacement for them. Sermorelin and Ipamorelin + Sermorelin sit in the same family.

One practical point: ipamorelin acts at the receptor ghrelin uses to signal hunger, so some people notice more appetite rather than less. None of these is a weight-loss medication on its own. See what is CJC-1295 / Ipamorelin.

MOTS-c is a mitochondrial-derived peptide described in mouse work as acting on skeletal muscle through AMPK, the cell's low-fuel sensor. Exercise raises the body's own MOTS-c in human muscle and blood; there are no human efficacy trials of the peptide itself. The MOTS-c reference puts it plainly: tirzepatide and MOTS-c are not competing for the same job. Tirzepatide reduces appetite; MOTS-c is described around fuel handling in muscle. What prescribers describe is subtle, such as better training tolerance and steadier afternoon energy. It is dosed Monday through Friday mornings. See what is MOTS-c and how to get MOTS-c prescribed.

5-Amino-1MQ is a small molecule described as inhibiting the enzyme NNMT in fat cells, with mouse data only. It is not a GLP-1 medication and does not act on appetite. It acts through an entirely different mechanism from tirzepatide, and some physicians prescribe them together, but there is no human study of the combination and no data on whether it adds anything. See what is 5-Amino-1MQ and how to get 5-Amino-1MQ prescribed.

AOD-9604 is a fragment of human growth hormone described around fat-cell signalling. It does not bind the growth hormone receptor and the human trials reported no change in IGF-1. It works through a mechanism unrelated to tirzepatide and some prescribers do combine them, but its large randomised human trial found no significant difference in weight loss against placebo, and there is no reason from the evidence to expect it to add to a GLP-1 medication's effect. The GLP-1 is the one with the evidence. See what is AOD-9604 and how to get AOD-9604 prescribed.

These put three or four of the agents above into one vial, so one injection covers several targets. PHYSIQ combines tesamorelin, ipamorelin, AOD-9604 and MOTS-c. SHRED combines AOD-9604, CJC-1295, ipamorelin and MOTS-c. FUSION combines BPC-157, MOTS-c, 5-Amino-1MQ and tesamorelin, and is positioned for use with or without a GLP-1. Patients commonly use these alongside tirzepatide or semaglutide; for anyone taking a blend that contains tesamorelin with a GLP-1, glucose is the thing the physician watches. Prescribers using FUSION alongside a GLP-1 describe less of the gut discomfort patients associate with the GLP-1; that has not been tested in a trial. See how to get SHRED prescribed.

NAD+ Injection is prescribed around cellular energy. The NAD+ reference is clear that it is not a weight or metabolic treatment: the precursor trials on insulin sensitivity were small and mixed. There is no study of NAD+ with tirzepatide. One practical note: NAD+ characteristically causes flushing, chest or abdominal tightness, or nausea during the injection, fading within minutes and blunted by injecting slowly. In the early weeks of tirzepatide, when nausea is most likely, two sources of queasiness are harder to tell apart, which is one reason to start them on different dates. See what is NAD+ and how to get NAD+ prescribed.

The tirzepatide reference calls L-carnitine and Lipo-B adjuncts rather than alternatives. L-carnitine is a cofactor that carries long-chain fatty acids into mitochondria; it does not suppress appetite, and the pathway still has to be driven by activity. What prescribers describe on it is training tolerance and recovery between sessions. It is injected into muscle, not under the skin. See what is L-carnitine and how to get L-carnitine prescribed.

For B12, the methylcobalamin reference puts it this way: if the plan is semaglutide or tirzepatide, B12 is a possible add-on, not the treatment. Lipo-Mino-Mix-C has no described interaction with a GLP-1 medication; on benefit, the GLP-1 is doing the work.

People often ask whether BPC-157 helps with tirzepatide's stomach side effects. The gut-health reference answers it directly: nausea, reflux and constipation on semaglutide or tirzepatide are a dose and titration question for the prescribing physician, not a reason to add a second vial. Most manageable GLP-1 nausea is managed by portion size, meal composition and titration pace. GLP-1 nausea: how to manage it covers what helps. BPC-157 is described in preclinical work around repair, and it appears in FUSION, but it is not a treatment for GLP-1 side effects.